Investment Banking
Bookrunner on Q32 Bio's $200.0 Million Follow-on Offering
July 22, 2026
Oppenheimer & Co. Inc. acted as Bookrunner on Q32 Bio's $200.0 Million Follow-on Offering
Q32 Bio Inc. (Nasdaq: OTTB ), ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, announced the pricing of its underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Q32 Bio has granted the underwriters a 30-day option to purchase up to an additional 1,643,835 shares of common stock at the public offering price. The gross proceeds to Q32 Bio from the offering are expected to be approximately $200.0 million, assuming no exercise of the underwriters' option to purchase additional shares and excluding any exercise of the pre-funded warrants.
Q32 Bio intends to use the net proceeds of the offering for working capital purposes, including expenses related to research, clinical development and commercialization efforts including for supporting the advancement of bempikibart into future clinical trials.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Name:
Dylan Gering
Title:Executive Director, Healthcare Life Sciences Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 9033077.1